HTPN 083: Give PrEP a Shot

HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV prevention in these populations.

Closed to enrollment, in active study follow-up

Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/